ExtendicareEXETF +1.32%76 Debt-to-EBITDA is 1.26 as of Mar. 2026, which is 75% below its 10-year median of 5.06. GuruFocus rates EXETF with a GF Score™ of 76/100 and a GF Value™ of $10.04 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 477 Healthcare Providers & Services companies, Extendicare ranks better than 62.47% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Extendicare's Debt-to-EBITDA or its related term are showing as below:
EXETF'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 1.48 Med: 5.06 Max: 7.76
Current: 1.48
During the past 13 years, the highest Debt-to-EBITDA Ratio of Extendicare was 7.76. The lowest was 1.48. And the median was 5.06.
EXETF's Debt-to-EBITDA is ranked better than 62.47% of 477
companies
in the Healthcare Providers & Services industry
Industry Median: 2.22
vs EXETF: 1.48
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Extendicare Debt-to-EBITDA Related Terms
Extendicare Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Extendicare's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Care Facilities subindustry, Extendicare's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Extendicare Debt-to-EBITDA vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Extendicare's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Extendicare's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Extendicare (EXETF) has a Debt-to-EBITDA of 1.26 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Extendicare. This is 75% below median its historical median of 5.06. Over the past decade, Extendicare's Debt-to-EBITDA has ranged from 1.48 to 7.76. According to the industry distribution chart, Extendicare ranks #179 out of 477 companies in the Healthcare Providers & Services industry, placing it in the top 37.5%.
Is Extendicare's Debt-to-EBITDA too high?
Extendicare's current Debt-to-EBITDA of 1.26 is 75% below median its 10-year median of 5.06. Over the past 10 years, this metric has ranged from a low of 1.48 to a high of 7.76. The Healthcare Providers & Services industry median Debt-to-EBITDA is 2.22. Extendicare's value of 1.26 is 43.2% below this industry median. Based on the distribution chart, Extendicare ranks #179 out of 477 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Extendicare has a GF Score™ of 76/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Extendicare's Debt-to-EBITDA compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Extendicare ranks #179 out of 477 companies for Debt-to-EBITDA. This puts Extendicare in the upper half of its industry. The industry median Debt-to-EBITDA is 2.22. Extendicare's value of 1.26 is 43.2% below this benchmark. Historically, Extendicare's own Debt-to-EBITDA has ranged from 1.48 to 7.76 over the past decade. While the company's 10-year median is 5.06 vs. the industry median of 2.22, Extendicare has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Healthcare Providers & Services company?
The median Debt-to-EBITDA among Healthcare Providers & Services companies is 2.22, based on 477 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Extendicare's current Debt-to-EBITDA of 1.26 is 43.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Extendicare. For the Healthcare Providers & Services industry, the median Debt-to-EBITDA is 2.22 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Extendicare's current Debt-to-EBITDA is 1.26, which is 75% below median its own 10-year median of 5.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Extendicare stock overvalued right now?
Based on GuruFocus' analysis, Extendicare (EXETF) is currently considered Significantly Overvalued. The stock's GF Value™ is $10.04, compared to a current price of $26.16 — trading 160.6% above its estimated fair value. The current Debt-to-EBITDA is 1.26, which is 75% below median its 10-year median of 5.06 and 43.2% below the Healthcare Providers & Services industry median of 2.22. Extendicare's overall GF Score™ is 76/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Extendicare (EXETF), the current Debt-to-EBITDA is 1.26 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Extendicare (EXETF) Overvalued in 2026?
Based on GuruFocus' analysis, Extendicare stock appears to be overvalued.
The current stock price of $26.16 is trading 160.6% above its estimated GF Value™ of $10.04.
GuruFocus considers Extendicare to be Significantly Overvalued.
Key valuation signals for EXETF:
Debt-to-EBITDA: 1.26 (75% below median its 10-year median of 5.06)
GF Value™: $10.04 vs. price of $26.16 (160.6% above fair value)
Industry Position: 43.2% below the Healthcare Providers & Services median (#179 of 477)
No single metric tells the full story. See the EXETF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Extendicare Inc is a senior care provider in Canada, focused on long-term care and home health care. The has three main business segments: Long-term Care (LTC), Home Health Care, and Managed Services. The Long-term Care segment, operating under the Extendicare brand, represents 53 owned homes in Ontario, Alberta and Manitoba. The Home Health Care segment, operating under the ParaMed brand, provides home health care services annually in Ontario, Alberta, Manitoba and Nova Scotia. The Managed Services segment, operating under the Extendicare Assist and SGP Purchasing Partner Network brands, provides management, consulting and group purchasing services to other care providers across Canada. The majority of the company's revenue is derived from the Long-term Care segment.
76GF Score
Get the complete analysis for EXETF
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
EXETF has been successfully added to your 
